Chris Howerton
Stock Analyst at Jefferies
(2.47)
# 2,333
Out of 4,893 analysts
74
Total ratings
42.37%
Success rate
13.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Howerton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Maintains: Buy | $11 → $8 | $4.56 | +75.63% | 5 | Jan 2, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $79 | $19.38 | +307.64% | 2 | Sep 29, 2023 | |
| MIST Milestone Pharmaceuticals | Downgrades: Hold | $8 → $4 | $1.56 | +156.41% | 4 | Jun 20, 2023 | |
| VERU Veru Inc. | Upgrades: Hold | $1 | $0.61 | +64.69% | 3 | Jun 7, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Hold | $320 → $352 | $1.96 | +17,859.18% | 2 | Mar 10, 2023 | |
| AVTX Avalo Therapeutics | Downgrades: Underperform | $720 | $4.85 | +14,745.36% | 2 | Feb 8, 2023 | |
| CGEN Compugen | Downgrades: Underperform | $0.5 | $1.61 | -68.94% | 2 | Feb 8, 2023 | |
| URGN UroGen Pharma | Downgrades: Hold | $35 → $10 | $14.26 | -29.87% | 1 | Feb 8, 2023 | |
| MEIP MEI Pharma | Downgrades: Underperform | $8 → $2 | $2.64 | -24.29% | 3 | Feb 8, 2023 | |
| AVDL Avadel Pharmaceuticals | Upgrades: Buy | $6.5 → $11 | $9.56 | +15.06% | 3 | Nov 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $70 → $40 | $19.41 | +106.08% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $57 → $61 | $34.14 | +78.68% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $90 | $109.58 | -17.87% | 3 | Sep 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $24 → $12 | $4.79 | +150.78% | 11 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $126 | $1.36 | +9,198.89% | 1 | Dec 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $1.42 | +1,308.45% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $66 | $23.03 | +186.58% | 9 | Sep 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $5.87 | +275.11% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $1.82 | +1,053.85% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $1.23 | +1,694.60% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.37 | +1,584.98% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $21 | $21.32 | -1.50% | 6 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $80 → $580 | $12.45 | +4,560.51% | 2 | Aug 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $63 → $60 | $1.18 | +4,984.75% | 1 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 | $71.76 | -77.70% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $53.32 | -49.36% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,200 | $8.70 | +13,693.10% | 1 | May 26, 2020 |
Ardelyx
Jan 2, 2025
Maintains: Buy
Price Target: $11 → $8
Current: $4.56
Upside: +75.63%
Structure Therapeutics
Sep 29, 2023
Maintains: Buy
Price Target: $50 → $79
Current: $19.38
Upside: +307.64%
Milestone Pharmaceuticals
Jun 20, 2023
Downgrades: Hold
Price Target: $8 → $4
Current: $1.56
Upside: +156.41%
Veru Inc.
Jun 7, 2023
Upgrades: Hold
Price Target: $1
Current: $0.61
Upside: +64.69%
BioXcel Therapeutics
Mar 10, 2023
Downgrades: Hold
Price Target: $320 → $352
Current: $1.96
Upside: +17,859.18%
Avalo Therapeutics
Feb 8, 2023
Downgrades: Underperform
Price Target: $720
Current: $4.85
Upside: +14,745.36%
Compugen
Feb 8, 2023
Downgrades: Underperform
Price Target: $0.5
Current: $1.61
Upside: -68.94%
UroGen Pharma
Feb 8, 2023
Downgrades: Hold
Price Target: $35 → $10
Current: $14.26
Upside: -29.87%
MEI Pharma
Feb 8, 2023
Downgrades: Underperform
Price Target: $8 → $2
Current: $2.64
Upside: -24.29%
Avadel Pharmaceuticals
Nov 30, 2022
Upgrades: Buy
Price Target: $6.5 → $11
Current: $9.56
Upside: +15.06%
Nov 10, 2022
Downgrades: Hold
Price Target: $70 → $40
Current: $19.41
Upside: +106.08%
Oct 14, 2022
Upgrades: Buy
Price Target: $57 → $61
Current: $34.14
Upside: +78.68%
Sep 30, 2022
Maintains: Buy
Price Target: $92 → $90
Current: $109.58
Upside: -17.87%
Feb 25, 2022
Downgrades: Hold
Price Target: $24 → $12
Current: $4.79
Upside: +150.78%
Dec 13, 2021
Maintains: Buy
Price Target: $101 → $126
Current: $1.36
Upside: +9,198.89%
Nov 30, 2021
Initiates: Buy
Price Target: $20
Current: $1.42
Upside: +1,308.45%
Sep 17, 2021
Initiates: Buy
Price Target: $66
Current: $23.03
Upside: +186.58%
Aug 23, 2021
Initiates: Buy
Price Target: $22
Current: $5.87
Upside: +275.11%
Aug 10, 2021
Initiates: Buy
Price Target: $21
Current: $1.82
Upside: +1,053.85%
May 25, 2021
Initiates: Buy
Price Target: $22
Current: $1.23
Upside: +1,694.60%
Apr 19, 2021
Initiates: Buy
Price Target: $23
Current: $1.37
Upside: +1,584.98%
Apr 6, 2021
Downgrades: Hold
Price Target: $40 → $21
Current: $21.32
Upside: -1.50%
Aug 11, 2020
Upgrades: Buy
Price Target: $80 → $580
Current: $12.45
Upside: +4,560.51%
Aug 7, 2020
Downgrades: Underperform
Price Target: $63 → $60
Current: $1.18
Upside: +4,984.75%
Aug 5, 2020
Downgrades: Hold
Price Target: $16
Current: $71.76
Upside: -77.70%
Jul 15, 2020
Initiates: Buy
Price Target: $27
Current: $53.32
Upside: -49.36%
May 26, 2020
Initiates: Buy
Price Target: $1,200
Current: $8.70
Upside: +13,693.10%